The company stated: “Given continuing uncertainties surrounding the U.S. market for HETLIOZ for the treatment of Non-24 as a result of continued generic competition in the U.S. and the upcoming commercial launches for Fanapt in acute bipolar I disorder and PONVORY in multiple sclerosis, Vanda is unable to provide 2024 financial guidance at this time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
- Vanda Pharmaceuticals up 16% after disclosing receipt of revised Future Pak bid
- Vanda confirms receipt of revised takeover bid from Future Pak
- VNDA Upcoming Earnings Report: What to Expect?
- Shareholder Capital delivers letter to board of Vanda Pharmaceuticals